Discover
ABCL
AbCellera Biologics Inc.
5.97
34 x 5.89
5 x 6.19
bid
ask
+
0.17
2.93%
04:00 PM
| Ytd | 74.56% | |
| 1y | 15.92% |
5.54
day range
6.05
2.75
52 week range
8.44
| Open | 5.81 | Prev Close | 5.80 | Low | 5.54 | High | 6.05 | Mkt Cap | 1.82B |
| Vol | 5.11M | Avg Vol | 8.17M | EPS | -0.48 | P/E | -12.44 | Forward P/E | 27.55 |
| Beta | 1.15 | Short Ratio | 6.28 | Inst. Own | 42.99% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 5.93 | 200-d Avg | 4.50 | 1yr Est | 10.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-05 | 2026-06 | -0.12 | N/A | N/A | N/A |
| 2026-05-11 | 2026-03 | -0.22 | -0.14 | 0.08 | 36.36% |
| 2026-02-24 | 2025-12 | -0.18 | -0.03 | 0.15 | 83.33% |
| 2025-11-06 | 2025-09 | -0.17 | -0.19 | -0.02 | -11.76% |
| 2025-08-07 | 2025-06 | -0.17 | -0.12 | 0.05 | 29.41% |
| 2025-05-08 | 2025-03 | -0.17 | -0.15 | 0.02 | 11.76% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-07-07 | Benchmark | Upgrade | Hold | Buy |
| 2026-05-05 | Cantor Fitzgerald | Upgrade | Overweight | |
| 2026-04-10 | Jones Trading | Upgrade | Buy | |
| 2025-11-07 | Leerink Partners | Downgrade | Outperform | Market Perform |
| 2025-08-08 | Stifel | Upgrade | Buy | Buy |
| 2025-07-14 | Keybanc | Upgrade | Overweight | Overweight |
Profile
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-02 | BOOTH ANDREW | Chief Financial Officer | 576.56K | Conversion of Exercise of derivative security |
| 2024-11-24 | HANSEN CARL L.G. | Chief Executive Officer | 56.98M | Conversion of Exercise of derivative security |
| 2026-05-13 | MONTALBANO JOHN S. | Director | 246.00K | Purchase |
| 2026-02-26 | THERMOPYLAE HOLDINGS, LTD. | Beneficial Owner of more than 10% of a Class of Security | 56.13M | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Baker Bros Advisors LP | 30.28M | 0.00 | 9.91% |
| 2026-03-30 | Capital World Investors | 13.36M | 0.00 | 4.38% |
| 2026-03-30 | Two Sigma Investments LLC | 10.56M | 0.00 | 3.46% |
| 2026-03-30 | TD Waterhouse Canada Inc | 9.56M | 0.00 | 3.13% |
| 2026-03-30 | UBS Asset Mgmt Americas Inc | 7.58M | 0.00 | 2.48% |
| 2025-12-30 | Two Sigma Advisers, LLC | 4.88M | 0.00 | 1.60% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | American Funds SMALLCAP World A | 13.36M | 0.00 | 4.38% |
| 2026-03-30 | UBS Lux Dgtl Hlth Eq Fd seeding P acc | 2.58M | 0.00 | 0.84% |
| 2026-05-30 | ACATIS Datini Valueflex Fonds A | 1.86M | 0.00 | 0.61% |
| 2026-06-29 | iShares Biotechnology ETF | 1.67M | 0.00 | 0.55% |
| 2026-06-29 | T. Rowe Price New Horizons | 1.05M | 0.00 | 0.35% |
| 2026-06-28 | Counterpoint Quantitative Equity ETF | 1.04M | 0.00 | 0.34% |